These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 39212861

  • 1. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
    Sun X, Lyu J, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov; 31(12):8179-8180. PubMed ID: 39212861
    [No Abstract] [Full Text] [Related]

  • 2. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.
    Sun X, Lyu J, Yang M, Lin Y, Wu K, Liu K, Li A, Shuai X, Cai K, Wang Z, Wang G, Zhang P, Yin Y, Tao K.
    Ann Surg Oncol; 2024 Nov; 31(12):8157-8169. PubMed ID: 39154154
    [Abstract] [Full Text] [Related]

  • 3. Chemotherapy for Esophageal Adenocarcinoma.
    Lam KO, Kwong DLW.
    Methods Mol Biol; 2018 Nov; 1756():19-34. PubMed ID: 29600357
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
    Park I, Ryu MH, Choi YH, Kang HJ, Yook JH, Park YS, Kim HJ, Jung HY, Lee GH, Kim KC, Kim BS, Kang YK.
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
    [Abstract] [Full Text] [Related]

  • 5. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
    Lorenzen S, Biederstädt A, Ronellenfitsch U, Reißfelder C, Mönig S, Wenz F, Pauligk C, Walker M, Al-Batran SE, Haller B, Hofheinz RD.
    BMC Cancer; 2020 Sep 15; 20(1):886. PubMed ID: 32933498
    [Abstract] [Full Text] [Related]

  • 6. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH.
    Surg Oncol Clin N Am; 2006 Oct 15; 15(4):803-24. PubMed ID: 17030275
    [Abstract] [Full Text] [Related]

  • 7. ASO Author Reflections: The Role of Adjuvant Chemotherapy in Adenocarcinoma of the Esophagogastric Junction.
    Luo TQ, Chen GM, Nie RC, Chen YB.
    Ann Surg Oncol; 2023 Jul 15; 30(7):4026-4027. PubMed ID: 36525208
    [No Abstract] [Full Text] [Related]

  • 8. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.
    Int J Cancer; 2015 Aug 01; 137(3):678-85. PubMed ID: 25530271
    [Abstract] [Full Text] [Related]

  • 9. A prospective phase II clinical trial of total neoadjuvant therapy for locally advanced gastric cancer and gastroesophageal junction adenocarcinoma.
    Shi JM, Li N, Jiang LM, Yang L, Wang SL, Song YW, Liu YP, Fang H, Lu NN, Qi SN, Chen B, Li YX, Zhao DB, Tang Y, Jin J.
    Sci Rep; 2024 Mar 29; 14(1):7522. PubMed ID: 38553594
    [Abstract] [Full Text] [Related]

  • 10. Histopathologic classification of adenocarcinoma of the esophagogastric junction.
    Baldus SE.
    Recent Results Cancer Res; 2010 Mar 29; 182():29-38. PubMed ID: 20676869
    [No Abstract] [Full Text] [Related]

  • 11. Role of repeat staging laparoscopy in locoregionally advanced gastric or gastroesophageal cancer after neoadjuvant therapy.
    Cardona K, Zhou Q, Gönen M, Shah MA, Strong VE, Brennan MF, Coit DG.
    Ann Surg Oncol; 2013 Feb 29; 20(2):548-54. PubMed ID: 22941159
    [Abstract] [Full Text] [Related]

  • 12. Challenges and considerations in interpreting the age-dependent benefit of neoadjuvant treatment for adenocarcinoma of the esophagus and gastroesophageal junction.
    Li K, Yan H, Ke T.
    Int J Surg; 2024 Sep 01; 110(9):5837-5840. PubMed ID: 38728858
    [No Abstract] [Full Text] [Related]

  • 13. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR, Gossage JA, Zylstra J, Mattsson F, Lagergren J, Maisey N, Smyth EC, Cunningham D, Allum WH, Mason RC.
    J Clin Oncol; 2014 Sep 20; 32(27):2983-90. PubMed ID: 25071104
    [Abstract] [Full Text] [Related]

  • 14. Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial.
    Shi J, Li N, Tang Y, Jiang L, Yang L, Wang S, Song Y, Liu Y, Fang H, Lu N, Qi S, Chen B, Li Z, Liu S, Wang J, Wang W, Zhu S, Yang J, Li Y, Zhao D, Jin J.
    BMC Gastroenterol; 2022 Jul 28; 22(1):359. PubMed ID: 35902798
    [Abstract] [Full Text] [Related]

  • 15. Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Fernandez E, Cacheux W, Frossard JL, Koessler T, Abou M, Moniez M, Huber O, Puppa G, Roth A.
    Dig Liver Dis; 2017 May 28; 49(5):552-556. PubMed ID: 28179095
    [Abstract] [Full Text] [Related]

  • 16. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C, Grenacher L, Siewert JR, Büchler M, Ott K.
    Ann Surg Oncol; 2014 May 28; 21(5):1739-48. PubMed ID: 24419755
    [Abstract] [Full Text] [Related]

  • 17. Letter to the editor for the article 'Efficacy and safety of neoadjuvant sintilimab in combination with FLOT chemotherapy in patients with HER2-negative locally advanced gastric or gastroesophageal junction adenocarcinoma: an investigator-initiated, single-arm, open-label, phase II study'.
    Wang L, Wu Q, Chi H, Yang G.
    Int J Surg; 2024 Sep 01; 110(9):6026-6027. PubMed ID: 38833345
    [No Abstract] [Full Text] [Related]

  • 18. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K, Tokunaga M, Mizusawa J, Machida N, Katayama H, Shitara K, Tomita T, Nakamura K, Boku N, Sano T, Terashima M, Sasako M, Stomach Cancer Study Group/Japan Clinical Oncology Group.
    Jpn J Clin Oncol; 2015 Nov 01; 45(11):1082-6. PubMed ID: 26355164
    [Abstract] [Full Text] [Related]

  • 19. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Briasoulis E, Fatouros M, Roukos DH.
    Ann Surg Oncol; 2007 Oct 01; 14(10):2691-5. PubMed ID: 17653806
    [No Abstract] [Full Text] [Related]

  • 20. Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis.
    Li J, Zhao Q, Ge X, Song Y, Tian Y, Wang S, Liu M, Qiao X.
    BMC Surg; 2021 Mar 17; 21(1):137. PubMed ID: 33731072
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.